Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



Upcoming Events

Dec 1, 2014
7:30 AM ET
Webcast Deutsche Bank 2014 BioFEST
Dec 3, 2014
8:30 AM ET
Webcast Piper Jaffray 26th Annual Healthcare Conference


View all releases Recent Press Releases

Nov 20, 2014 Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Nov 19, 2014 Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
Nov 18, 2014 Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
Nov 11, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
Nov 4, 2014 Regeneron Reports Third Quarter 2014 Financial and Operating Results
Nov 3, 2014 Regeneron Announces Upcoming 2014 Investor Conference Presentations
Oct 20, 2014 Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Oct 17, 2014 EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Oct 16, 2014 Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year
Oct 16, 2014 Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments


Close
Form content here please :)